Mlh1 selective (series 1b) compounds
AssigneeNeoPhore Limited
InventorsJulian Blagg, Martin Drysdale, Paul Winship, Stuart Rankin, Alastair Rae, Jacob Bestwick
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeoPhore Limited
InventorsJulian Blagg, Martin Drysdale, Paul Winship, Stuart Rankin, Alastair Rae, Jacob Bestwick
Estimating the term…
The present invention relates to compounds of Formula (I) that target MLH1, a component of the DNA Mismatch Repair (MMR) process: wherein R2, R3, R4, R5, Y1, Y2, A1, A2, A3, and A4 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 activity is implicated (e.g. Triplet Repeat Disorders).
A compound, or a pharmaceutically acceptable salt thereof, having the structural Formula (I) shown below:
The compound, or pharmaceutically acceptable salts thereof, according to any preceding claim, wherein the compound is selected from any one of the following:
A pharmaceutical composition comprising a compound as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
Dependencies are inferred from the claim text.